Ignyta Announces Results for Potential New Cancer Treatment

Dr. Alexander Drilon of Memorial Sloan Kettering Cancer Center recently reported at AACR on a potential new cancer treatment, Entrectinib, a receptor tyrosine kinase (RTK) inhibitor developed to target tumors carrying NTRK1, NTRK2, NTRK3, [...]